These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38710206)

  • 21. Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial.
    Sepanjnia K; Modabbernia A; Ashrafi M; Modabbernia MJ; Akhondzadeh S
    Neuropsychopharmacology; 2012 Aug; 37(9):2093-100. PubMed ID: 22549115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.
    Soares CN; Thase ME; Clayton A; Guico-Pabia CJ; Focht K; Jiang Q; Kornstein SG; Ninan PT; Kane CP
    CNS Drugs; 2011 Mar; 25(3):227-38. PubMed ID: 21323394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Double-blind, randomized, placebo-controlled pilot study of the phosphodiesterase-3 inhibitor cilostazol as an adjunctive to antidepressants in patients with major depressive disorder.
    Abdallah MS; Ramadan AN; Omara-Reda H; Mansour NO; Elsokary MA; Elsawah HK; Zaki SA; Abo Mansour HE; Mosalam EM
    CNS Neurosci Ther; 2021 Dec; 27(12):1540-1548. PubMed ID: 34545997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
    Lenox-Smith AJ; Jiang Q
    Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vitamin C as an adjuvant for treating major depressive disorder and suicidal behavior, a randomized placebo-controlled clinical trial.
    Sahraian A; Ghanizadeh A; Kazemeini F
    Trials; 2015 Mar; 16():94. PubMed ID: 25873303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    Mathews M; Gommoll C; Chen D; Nunez R; Khan A
    Int Clin Psychopharmacol; 2015 Mar; 30(2):67-74. PubMed ID: 25500685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
    Fourrier C; Sampson E; Mills NT; Baune BT
    Trials; 2018 Aug; 19(1):447. PubMed ID: 30126458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
    J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of empagliflozin as adjunctive therapy to citalopram in major depressive disorder: a randomized double-blind, placebo-controlled clinical trial.
    Zandifar A; Panahi M; Badrfam R; Qorbani M
    BMC Psychiatry; 2024 Feb; 24(1):163. PubMed ID: 38408937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. L-Carnosine combination therapy for major depressive disorder: A randomized, double-blind, placebo-controlled trial.
    Araminia B; Shalbafan M; Mortezaei A; Shirazi E; Ghaffari S; Sahebolzamani E; Mortazavi SH; Shariati B; Ardebili ME; Aqamolaei A; Naderi S; Akhondzadeh S
    J Affect Disord; 2020 Apr; 267():131-136. PubMed ID: 32063564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Agomelatine and Fluoxetine on HAM-D Score, Serum Brain-Derived Neurotrophic Factor, and Tumor Necrosis Factor-α Level in Patients With Major Depressive Disorder With Severe Depression.
    Gupta K; Gupta R; Bhatia MS; Tripathi AK; Gupta LK
    J Clin Pharmacol; 2017 Dec; 57(12):1519-1526. PubMed ID: 28833192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study.
    Brown ES; Howard C; Khan DA; Carmody TJ
    Psychosomatics; 2012; 53(1):75-80. PubMed ID: 22221724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study.
    Ou JJ; Xun GL; Wu RR; Li LH; Fang MS; Zhang HG; Xie SP; Shi JG; Du B; Yuan XQ; Zhao JP
    Psychopharmacology (Berl); 2011 Feb; 213(2-3):639-46. PubMed ID: 20340011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. S-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response.
    Sarris J; Papakostas GI; Vitolo O; Fava M; Mischoulon D
    J Affect Disord; 2014 Aug; 164():76-81. PubMed ID: 24856557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
    Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
    CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
    Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
    Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Topiramate augmentation in patients with resistant major depressive disorder: a double-blind placebo-controlled clinical trial.
    Mowla A; Kardeh E
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):970-3. PubMed ID: 21291943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute antidepressive efficacy of lithium monotherapy, not citalopram, depends on recurrent course of depression.
    Bschor T; Uhr M; Baethge C; Lewitzka U; Ising M; Erbe S; Winkelmann P; Ritter D
    J Clin Psychopharmacol; 2013 Feb; 33(1):38-44. PubMed ID: 23277245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.